In plain English
Sermorelin is the shortest piece of your body’s own growth hormone-releasing hormone that still works. It gently nudges the pituitary gland to release growth hormone in natural pulses. It has been used for decades and is often the first growth hormone peptide people try.
What it's used for
- Natural growth hormone support with age
- Sleep quality and recovery
- Body composition
- Energy and general wellbeing
Benefits
In human studies, sermorelin has been shown to:
- Raise growth hormone and IGF-1 in adults and children
- Improve growth in children with growth hormone deficiency (its original medical use)
- Improve lean body mass and skin thickness in older adults in small studies
Users report deeper sleep, more energy and better recovery over a few months.
How it works
In simple terms: sermorelin gives your pituitary the same signal your brain naturally sends to release growth hormone.
It is the first 29 amino acids of growth hormone-releasing hormone (GHRH), the part that carries all its activity. It binds GHRH receptors on the pituitary, which releases growth hormone in pulses; your body’s own feedback controls still apply, which makes it a gentle approach. Because it breaks down within minutes, it is dosed daily, usually at night.
Development history
- 1980s: Developed after scientists identified the active fragment of GHRH.
- 1990s: Sold as Geref for children with growth hormone deficiency.
- 2008: Geref was discontinued by its maker for business reasons.
- Today: Widely used in anti-aging and wellness clinics and as a research peptide.
Typical protocols
These ranges are what users commonly report.
| Use | Dose | Frequency | Notes |
|---|---|---|---|
| Standard | 200–300 mcg | Once daily, before bed | Empty stomach |
| Higher range | Up to 500 mcg | Once daily, before bed | After a few weeks at the standard dose |
Many users follow a 5-days-on, 2-days-off schedule and pair sermorelin with ipamorelin.
Cycling
Commonly used for 3–6 months, often with weekends off, followed by a break.
Administration options
Subcutaneous injection once daily, usually at bedtime.
Reconstitution and dosing calculator
Sermorelin usually comes in 2 mg to 15 mg vials and is commonly mixed with 2–3 mL of bacteriostatic water.
Draw your syringe to
– units
- Volume to draw
- –
- Concentration
- –
- Each unit holds
- –
- Doses per vial
- –
Show the math
This tool does arithmetic only. It does not choose a dose or confirm that any substance is right for you. Double-check every result against your syringe and your clinician’s instructions.
Side effects and safety
- Users report that sermorelin is generally well tolerated. Occasional effects include injection-site redness or swelling, facial flushing, headache and dizziness.
- Raising growth hormone can affect blood sugar; people with diabetes should be cautious.
- People with active cancer are usually advised to avoid growth hormone-raising peptides.
- Prohibited in competitive sport (WADA).
Common stacks
- Ipamorelin: the most common pairing, for a stronger growth hormone pulse.
- GHRP-2 or GHRP-6: older pairings with stronger effects and more side effects.
Storage
Powder: refrigerate, dry and away from light.
After mixing: refrigerate at 2–8 °C, protect from light, and use within about 3–4 weeks.
Compare with
- CJC-1295: a modified GHRH peptide that lasts longer (especially the DAC version).
- Tesamorelin: a stabilized full-length GHRH with strong belly-fat data.
Frequently asked questions
Is sermorelin the same as growth hormone?
No. It prompts your body to make more of its own growth hormone rather than supplying it directly.
Why inject at night?
The body releases most of its growth hormone during deep sleep, and sermorelin works with that rhythm.
How long until results?
Users report better sleep within a few weeks; other changes build over 3–6 months.
Sermorelin or CJC-1295?
Sermorelin is shorter-acting and gentler; CJC-1295 is longer-lasting. Both are commonly paired with ipamorelin.
References
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.